Discussion Forums > Working Towards a Cure

Gene Transfer Therapy Stage 1 Clinical Trials at Sloan Kettering

<< < (8/15) > >>

Canadian_Family:
Thanks for the update from Pat.

Regards,

catchR:
Many thanks for the update.

Hoping for the best!!

Sharmin:
thank you for sharing Parin!  My prayers are with SK!

Sharmin

Canadian_Family:
The estimated time for study completion extended to July 2016. SMKCC keeps delaying the results outcome. This was originally planned for July 2014. Follow the link below.

https://clinicaltrials.gov/ct2/show/study/NCT01639690

Andy Battaglia:
At this point, the only question I have about SK is have the people at the top invested in Bluebird? Information from SK has dried up and no new patients have been started for at least 18 months. The fact that Pat G can't get any info out of them is troubling. Meanwhile, Dr Sadelain has become a co-founder of Juno Therapeutics.

Went Public on Nov 14, 2014 / NASDAQ:JUNO
Funding Received
$310 Million in 3 Rounds from 4 Investors
Headquarters:
Seattle, WA
Description:
Juno Therapeutics, a clinical-stage company, develops immunotherapies for the treatment of cancer.
Founders:
Michael Jensen, Michel Sadelain, Isabelle Rivière, Stan Riddell, Phil Greenberg, Renier Brentjens
Categories:
Health and Wellness, Health Care, Biotechnology
Website:
http://junotherapeutics.com

Navigation

[0] Message Index

[#] Next page

[*] Previous page